Market Overview

UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin Expansion Visibility

Related GSK
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
Tracking The Hotchkis & Wiley Value Opportunities Fund - Q3 2015 Update (Seeking Alpha)

Jefferies cut its rating on GlaxoSmithKline (NYSE: GSK) from Buy to Hold on reduced visibility to the company's margin expansion.

Jefferies commented, "Whilst we still see double digit CORE EPS growth for GlaxoSmithKline from 2013E-17E, visibility on margin expansion has been obscured by over-exposure to price pressure and transfer pricing in Europe. The shares have recovered well from their lows since the Q2'12 results and we take this opportunity to cut our rating to Hold from Buy given the limited upside."

GlaxoSmithKline closed at $46.84 on Friday.

Latest Ratings for GSK

Oct 2015Credit SuisseUpgradesUnderperformNeutral
Oct 2015JP MorganUpgradesUnderweightNeutral
Jun 2015Morgan StanleyDowngradesOverweightEqualweight

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters